Literature DB >> 8763932

Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.

X S Pan1, L M Fisher.   

Abstract

DNA topoisomerase IV mediates chromosome segregation and is a potential target for antibacterial agents including new antipneumococcal fluoroquinolones. We have used hybridization to a Staphylococcus aureus gyrB probe in concert with chromosome walking to isolate the Streptococcus pneumoniae parE-parC locus, lying downstream of a putative new insertion sequence and encoding 647-residue ParE and 823-residue ParC subunits of DNA topoisomerase IV. These proteins exhibited greatest homology respectively to the GrlB (ParE) and GrlA (ParC) subunits of S. aureus DNA topoisomerase IV. When combined, whole-cell extracts of Escherichia coli strains expressing S. pneumoniae ParC or ParE proteins reconstituted a salt-insensitive ATP-dependent decatenase activity characteristic of DNA topoisomerase IV. A second gyrB homolog isolated from S. pneumoniae encoded a 648-residue protein which we identified as GyrB through its close homology both to counterparts in S. aureus and Bacillus subtilis and to the product of the S. pneumoniae nov-1 gene that confers novobiocin resistance. gyrB was not closely linked to gyrA. To examine the role of DNA topoisomerase IV in fluoroquinolone action and resistance in S. pneumoniae, we isolated mutant strains stepwise selected for resistance to increasing concentrations of ciprofloxacin. We analysed four low-level resistant mutants and showed that Ser-79 of ParC, equivalent to resistance hotspots Ser-80 of GrlA and Ser-84 of GyrA in S. aureus, was in each case substituted with Tyr. These results suggest that DNA topoisomerase IV is an important target for fluoroquinolones in S. pneumoniae and establish this organism as a useful gram-positive system for resistance studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763932      PMCID: PMC178161          DOI: 10.1128/jb.178.14.4060-4069.1996

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  36 in total

1.  A sign inversion mechanism for enzymatic supercoiling of DNA.

Authors:  P O Brown; N R Cozzarelli
Journal:  Science       Date:  1979-11-30       Impact factor: 47.728

2.  DNA gyrase: an enzyme that introduces superhelical turns into DNA.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; H A Nash
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

3.  DNA gyrase action involves the introduction of transient double-strand breaks into DNA.

Authors:  K Mizuuchi; L M Fisher; M H O'Dea; M Gellert
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

4.  Mapping the active site tyrosine of Escherichia coli DNA gyrase.

Authors:  D S Horowitz; J C Wang
Journal:  J Biol Chem       Date:  1987-04-15       Impact factor: 5.157

5.  Energy coupling in DNA gyrase and the mechanism of action of novobiocin.

Authors:  A Sugino; N P Higgins; P O Brown; C L Peebles; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

6.  Cloning and simplified purification of Escherichia coli DNA gyrase A and B proteins.

Authors:  K Mizuuchi; M Mizuuchi; M H O'Dea; M Gellert
Journal:  J Biol Chem       Date:  1984-07-25       Impact factor: 5.157

7.  Structure and function of the region of the replication origin of the Bacillus subtilis chromosome. III. Nucleotide sequence of some 10,000 base pairs in the origin region.

Authors:  S Moriya; N Ogasawara; H Yoshikawa
Journal:  Nucleic Acids Res       Date:  1985-04-11       Impact factor: 16.971

8.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.

Authors:  L Ferrero; B Cameron; J Crouzet
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more
  87 in total

1.  Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.

Authors:  V J Heaton; C E Goldsmith; J E Ambler; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

2.  Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.

Authors:  S Brisse; A C Fluit; U Wagner; P Heisig; D Milatovic; J Verhoef; S Scheuring; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

3.  Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.

Authors:  M E Jones; D F Sahm; N Martin; S Scheuring; P Heisig; C Thornsberry; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

4.  New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.

Authors:  C Janoir; E Varon; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.

Authors:  M Boos; S Mayer; A Fischer; K Köhrer; S Scheuring; P Heisig; J Verhoef; A C Fluit; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

6.  Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones.

Authors:  L Alou; M Ramirez; C García-Rey; J Prieto; H de Lencastre
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

7.  Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae.

Authors:  D C Richardson; D Bast; A McGeer; D E Low
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

8.  Sequence analysis of the gyrA and parC homologues of a wild-type strain of Vibrio parahaemolyticus and its fluoroquinolone-resistant mutants.

Authors:  J Okuda; E Hayakawa; M Nishibuchi; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

9.  Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

10.  In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.

Authors:  T A Davies; G A Pankuch; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.